 Home > Active Ingredient News > Antitumor Therapy > Ann Oncol: Second-line Osimertinib (osimertinib) combined with bevacizumab does not significantly improve the prognosis of patients with T790M mutation in EGFR-mutant advanced NSCLC

Ann Oncol: Second-line Osimertinib (osimertinib) combined with bevacizumab does not significantly improve the prognosis of patients with T790M mutation in EGFR-mutant advanced NSCLC

 Last Update: 2022-03-04
 Source: Internet
 Author: User

Tags

brain cancer survival

chemistry grade 10

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Osimertinib (Osimertinib) is the standard second-line treatment for patients with EGFR-mutant NSCLC who acquire the T790M mutation, and the efficacy of its combination with bevacizumab is unclear
.

Therefore, the results of a phase II study, BOOSTER, were published in Annals of Oncology, evaluating second-line Osimertinib (osimertinib) combined with bevacizumab versus Osimertinib (osimertinib) monotherapy in patients with EGFR T790M-mutated advanced NSCLC.

Osimertinib (Osimertinib) is the standard second-line treatment for patients with EGFR-mutant NSCLC who acquire the T790M mutation, and the efficacy of its combination with bevacizumab is unclear

The BOOSTER study is an open-label, randomized Phase II clinical study
.

The primary study endpoint was investigator-assessed progression-free survival (PFS)

The BOOSTER study is an open-label, randomized Phase II clinical study

Between May 2017 and February 2019, 155 patients were randomized (combination arm: 78; single-agent arm: 77)

The median follow-up time was 33.

PFS

In subgroup analysis, the combination group improved median PFS in current and former smokers [HR: 0.
57 (0.
33-0.
98); Wald's test P=0.
043], but not in non-smokers (HR: 1.
29 ( 0.
82-2.
02); Wald's test P=0.
28)
.

In subgroup analysis, the combination group improved median PFS in current and former smokers [HR: 0.

Differences in PFS treated with different smoking status

Median OS was 24.
0 months (95% CI 17.
8-32.
1) in the combination arm versus 24.
3 months (95% CI 16.
9-37.
0) in the monotherapy arm, with no significant difference in OS [log-rank P =0.
89; HR: 1.
03 (0.
68-1.
56)
.

The combination group numerically prolonged median OS in current and former smokers [HR: 0.

Median OS was 24.

Differences in OS between different smoking statuses

ORR was 55% (95% CI 43%-66%) in both treatment arms and DCR was 90% (95% CI 81%-95%) and 82% (95%) in the combination arm and monotherapy arm, respectively CI 71%-90%) (P=0.
17)
.

ORR was 55% (95% CI 43%-66%) in both treatment arms and DCR was 90% (95% CI 81%-95%) and 82% (95%) in the combination arm and monotherapy arm, respectively CI 71%-90%) (P=0.

In the safety cohort, 152 of 153 patients (99%) experienced at least one AE of any grade (76 in each group)

In conclusion, the study showed that Osimertinib (osimertinib) combined with bevacizumab second-line therapy did not significantly improve the prognosis of patients with T790M mutation in EGFR-mutant advanced NSCLC
.
Studies have shown that Osimertinib (osimertinib) combined with bevacizumab second-line therapy does not significantly improve the prognosis of patients with T790M mutation in EGFR-mutant advanced NSCLC
.
Studies have shown that Osimertinib (osimertinib) combined with bevacizumab second-line therapy does not significantly improve the prognosis of patients with T790M mutation in EGFR-mutant advanced NSCLC
.

Original source:

Soo RA, Han JY, Dafni U, et al.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10- 16) BOOSTER trial.
Ann Oncol.
2022 Feb;33(2):181-192.
doi: 10.
1016/j.
annonc.
2021.
11.
010.
Epub 2021 Nov 26.
PMID: 34839016.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.